<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30411159</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1432-0711</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Archives of gynecology and obstetrics</Title>                <ISOAbbreviation>Arch. Gynecol. Obstet.</ISOAbbreviation>            </Journal>            <ArticleTitle>Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00404-018-4954-7</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To examine influences on the receptor status of a local cohort of patients with recurrent breast cancer after primary diagnosis of hormone receptor positive breast cancer.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed 2078 female patients with primary hormone receptor positive breast cancer treated at the university hospital of Wuerzburg between 2000 and 2013. Main focus was on discordance in receptor status in recurrent disease.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">196 patients with the primary diagnosis of hormone receptor positive breast cancer developed recurrent disease. 29.1% of patients revealed discordance in estrogen receptor (ER), progesterone receptor (PgR) or HER2 receptor (ER<sup>+</sup> to <sup>-</sup>: 33.3%; PgR<sup>+</sup> to <sup>-</sup>: 59.6%; HER2<sup>+</sup> to <sup>-</sup>: 8.8%; HER2<sup>-</sup> to <sup>+</sup>: 17.5%). Aggressive tumor biology such as low grading or involvement of axillary lymph nodes showed increased risk of receptor conversion in relapse. Premenopausal patients with adjuvant application of tamoxifen and the application of chemotherapy had a significantly lower risk for the development of ER negative recurrent disease. Receptor changes to ER and PgR negativity in recurrent disease showed a trend to worse overall survival (OS).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Histological analysis of recurrent disease is indispensable, since one-third of patients with hormone receptor positive breast cancer develop change in the receptor status.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Stueber</LastName>                    <ForeName>Tanja Nadine</ForeName>                    <Initials>TN</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0145-5739</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology and Obstetrics, University Hospital Wuerzburg, Josef-Schneider-Str. 4, 97080, Wuerzburg, Germany. Stueber_T@ukw.de.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Weiss</LastName>                    <ForeName>Claire Rachel</ForeName>                    <Initials>CR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Charité, Campus Virchow, University Hospital Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Woeckel</LastName>                    <ForeName>Achim</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology and Obstetrics, University Hospital Wuerzburg, Josef-Schneider-Str. 4, 97080, Wuerzburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haeusler</LastName>                    <ForeName>Sebastian</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology and Obstetrics, University Hospital Wuerzburg, Josef-Schneider-Str. 4, 97080, Wuerzburg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, University of Regensburg, Hospital of the Order of St. John of God Regensburg-St. Hedwig Clinic, Steinmetzstraße 1-3, 93049, Regensburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Arch Gynecol Obstet</MedlineTA>            <NlmUniqueID>8710213</NlmUniqueID>            <ISSNLinking>0932-0067</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Hormone receptor</Keyword>            <Keyword MajorTopicYN="N">Receptor discordance</Keyword>            <Keyword MajorTopicYN="N">Recurrent disease</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30411159</ArticleId>            <ArticleId IdType="doi">10.1007/s00404-018-4954-7</ArticleId>            <ArticleId IdType="pii">10.1007/s00404-018-4954-7</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>